Dr. Le is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
401 N Broadway
Baltimore, MD 21231Phone+1 410-287-0002Fax+1 410-614-8216
Summary
- Dung Le, MD, is an oncologist based in Baltimore, MD, with a subspecialty in Hematologic Oncology. She completed her education and training at the prestigious Johns Hopkins University School of Medicine, where she also completed a fellowship in Hematology and Medical Oncology. Dr. Le has extensive experience in gastrointestinal oncology and general medical oncology, with several publications in reputable journals including the Journal for Immunotherapy of Cancer and Clinical Cancer Research. She is currently involved in multiple clinical trials focusing on advanced solid tumors and pancreatic cancer. In 2013-2014, Dr. Le received the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
- Johns Hopkins UniversityResidency, Internal Medicine, 2001 - 2004
- Johns Hopkins University School of MedicineClass of 2001
Certifications & Licensure
- MD State Medical License 2004 - 2026
- NH State Medical License 2024 - 2024
- PA State Medical License 2020 - 2024
- NC State Medical License 2020 - 2022
- ME State Medical License 2020 - 2021
- OK State Medical License 2021 - 2021
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer Start of enrollment: 2009 Feb 01
- QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Start of enrollment: 2012 Jan 01
- Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer Start of enrollment: 2011 Sep 21
- Join now to see all
Publications & Presentations
PubMed
- 1232 citationsPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.Thierry André, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen
The New England Journal of Medicine. 2020-12-03 - 1512 citationsEfficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta
Journal of Clinical Oncology. 2020-01-01 - 870 citationsPrimary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.Daniel Sanghoon Shin, Jesse M. Zaretsky, Helena Escuin-Ordinas, Angel Garcia-Diaz, Siwen Hu-Lieskovan
Cancer Discovery. 2017-02-01
Press Mentions
- Immunotherapy for Colon CancerSeptember 4th, 2019
- Tumor Gene Testing Urged to Tell if Drug Targets Your CancerJuly 6th, 2017
- Nivolumab Improves OS in Phase III Gastric Cancer StudyNovember 10th, 2016
Other Languages
- Vietnamese
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/dung-le
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: